Effect of soy on bone turn-over markers in men with type 2 diabetes and hypogonadism - A randomised controlled study

T. Sathyapalan, M. Aye, A. S. Rigby, W. D. Fraser, E. S. Kilpatrick, Stephen Atkin

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Type 2 diabetes (T2DM) is associated with increased risk of fractures. Soy supplementation has been shown to have a beneficial effect on bone turnover markers (BTM) in postmenopausal women. However, the effect of soy supplementation on BTM in T2DM and particularly in men is unclear. We performed an analysis of a randomized double blind parallel study of 200 men with T2DM treated with soy, either with or without isoflavones. Outcome measures were type I collagen crosslinked beta C-telopeptide (βCTX), and type 1 procollagen-N-propeptide (P1NP). The men, with a total testosterone <12 nmol/L, were treated with 15 g soy protein containing 66 mg of isoflavones (SPI) or 15 g soy protein alone without isoflavones (SP) daily for three months. There was a 15% reduction in βCTX after three months of SPI compared to SP supplementation. There was no significant difference in P1NP with either SPI or SP supplementation. There was a significant linear correlation between the reduction in βCTX in the SPI group with the reduction in HbA1c (r2 = 0.42; p = 0.04) and HOMA-IR (r2 = 0.54; p = 0.02). Our study indicates that there was a significant reduction in bone resorption following 3 months of SPI supplementation that correlated with an improvement of glycemic control in men with T2DM.

Original languageEnglish
Article number15366
JournalScientific Reports
Volume7
Issue number1
DOIs
Publication statusPublished - 1 Dec 2017

Fingerprint

Hypogonadism
Type 2 Diabetes Mellitus
Isoflavones
Bone and Bones
Soybean Proteins
Bone Remodeling
Collagen Type I
Bone Resorption
Double-Blind Method
Testosterone
Outcome Assessment (Health Care)

ASJC Scopus subject areas

  • General

Cite this

Effect of soy on bone turn-over markers in men with type 2 diabetes and hypogonadism - A randomised controlled study. / Sathyapalan, T.; Aye, M.; Rigby, A. S.; Fraser, W. D.; Kilpatrick, E. S.; Atkin, Stephen.

In: Scientific Reports, Vol. 7, No. 1, 15366, 01.12.2017.

Research output: Contribution to journalArticle

Sathyapalan, T. ; Aye, M. ; Rigby, A. S. ; Fraser, W. D. ; Kilpatrick, E. S. ; Atkin, Stephen. / Effect of soy on bone turn-over markers in men with type 2 diabetes and hypogonadism - A randomised controlled study. In: Scientific Reports. 2017 ; Vol. 7, No. 1.
@article{1e9abead597e4447845c40827c022aa2,
title = "Effect of soy on bone turn-over markers in men with type 2 diabetes and hypogonadism - A randomised controlled study",
abstract = "Type 2 diabetes (T2DM) is associated with increased risk of fractures. Soy supplementation has been shown to have a beneficial effect on bone turnover markers (BTM) in postmenopausal women. However, the effect of soy supplementation on BTM in T2DM and particularly in men is unclear. We performed an analysis of a randomized double blind parallel study of 200 men with T2DM treated with soy, either with or without isoflavones. Outcome measures were type I collagen crosslinked beta C-telopeptide (βCTX), and type 1 procollagen-N-propeptide (P1NP). The men, with a total testosterone <12 nmol/L, were treated with 15 g soy protein containing 66 mg of isoflavones (SPI) or 15 g soy protein alone without isoflavones (SP) daily for three months. There was a 15{\%} reduction in βCTX after three months of SPI compared to SP supplementation. There was no significant difference in P1NP with either SPI or SP supplementation. There was a significant linear correlation between the reduction in βCTX in the SPI group with the reduction in HbA1c (r2 = 0.42; p = 0.04) and HOMA-IR (r2 = 0.54; p = 0.02). Our study indicates that there was a significant reduction in bone resorption following 3 months of SPI supplementation that correlated with an improvement of glycemic control in men with T2DM.",
author = "T. Sathyapalan and M. Aye and Rigby, {A. S.} and Fraser, {W. D.} and Kilpatrick, {E. S.} and Stephen Atkin",
year = "2017",
month = "12",
day = "1",
doi = "10.1038/s41598-017-15402-9",
language = "English",
volume = "7",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

TY - JOUR

T1 - Effect of soy on bone turn-over markers in men with type 2 diabetes and hypogonadism - A randomised controlled study

AU - Sathyapalan, T.

AU - Aye, M.

AU - Rigby, A. S.

AU - Fraser, W. D.

AU - Kilpatrick, E. S.

AU - Atkin, Stephen

PY - 2017/12/1

Y1 - 2017/12/1

N2 - Type 2 diabetes (T2DM) is associated with increased risk of fractures. Soy supplementation has been shown to have a beneficial effect on bone turnover markers (BTM) in postmenopausal women. However, the effect of soy supplementation on BTM in T2DM and particularly in men is unclear. We performed an analysis of a randomized double blind parallel study of 200 men with T2DM treated with soy, either with or without isoflavones. Outcome measures were type I collagen crosslinked beta C-telopeptide (βCTX), and type 1 procollagen-N-propeptide (P1NP). The men, with a total testosterone <12 nmol/L, were treated with 15 g soy protein containing 66 mg of isoflavones (SPI) or 15 g soy protein alone without isoflavones (SP) daily for three months. There was a 15% reduction in βCTX after three months of SPI compared to SP supplementation. There was no significant difference in P1NP with either SPI or SP supplementation. There was a significant linear correlation between the reduction in βCTX in the SPI group with the reduction in HbA1c (r2 = 0.42; p = 0.04) and HOMA-IR (r2 = 0.54; p = 0.02). Our study indicates that there was a significant reduction in bone resorption following 3 months of SPI supplementation that correlated with an improvement of glycemic control in men with T2DM.

AB - Type 2 diabetes (T2DM) is associated with increased risk of fractures. Soy supplementation has been shown to have a beneficial effect on bone turnover markers (BTM) in postmenopausal women. However, the effect of soy supplementation on BTM in T2DM and particularly in men is unclear. We performed an analysis of a randomized double blind parallel study of 200 men with T2DM treated with soy, either with or without isoflavones. Outcome measures were type I collagen crosslinked beta C-telopeptide (βCTX), and type 1 procollagen-N-propeptide (P1NP). The men, with a total testosterone <12 nmol/L, were treated with 15 g soy protein containing 66 mg of isoflavones (SPI) or 15 g soy protein alone without isoflavones (SP) daily for three months. There was a 15% reduction in βCTX after three months of SPI compared to SP supplementation. There was no significant difference in P1NP with either SPI or SP supplementation. There was a significant linear correlation between the reduction in βCTX in the SPI group with the reduction in HbA1c (r2 = 0.42; p = 0.04) and HOMA-IR (r2 = 0.54; p = 0.02). Our study indicates that there was a significant reduction in bone resorption following 3 months of SPI supplementation that correlated with an improvement of glycemic control in men with T2DM.

UR - http://www.scopus.com/inward/record.url?scp=85034262059&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85034262059&partnerID=8YFLogxK

U2 - 10.1038/s41598-017-15402-9

DO - 10.1038/s41598-017-15402-9

M3 - Article

VL - 7

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 15366

ER -